HALO vs JNJ

For growth investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger pick with 37. 6% revenue growth year-over-year, versus 4. 3% for Johnson & Johnson (JNJ). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 9x trailing P/E (8. 2x forward), making it the more compelling value choice. Analysts rate Halozyme Therapeutics, Inc. (HALO) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Halozyme Therapeutics, Inc.

(HALO) is the cheapest at 25. 9x versus Johnson & Johnson at 38. 8x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Halozyme Therapeutics, Inc. wins at 0. 36x versus Johnson & Johnson's 34. 49x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +48.

0%, compared to +39. 1% for Halozyme Therapeutics, Inc. (HALO). Over 10 years, the gap is even starker: HALO returned +598. 4% versus JNJ's +136. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus Halozyme Therapeutics, Inc. 's 0. 56β — meaning HALO is approximately 879% more volatile than JNJ relative to the S&P 500.

By revenue growth (latest reported year), Halozyme Therapeutics, Inc.

(HALO) is pulling ahead at 37. 6% versus 4. 3% for Johnson & Johnson (JNJ). On earnings-per-share growth, the picture is similar: Halozyme Therapeutics, Inc. grew EPS -25. 4% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus 15. 8% for Johnson & Johnson — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 24. 9% for JNJ. At the gross margin level — before operating expenses — HALO leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Halozyme Therapeutics, Inc. (HALO) is the more undervalued stock at a PEG of 0. 36x versus Johnson & Johnson's 34. 49x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Halozyme Therapeutics, Inc. (HALO) trades at 8. 2x forward P/E versus 19. 4x for Johnson & Johnson — 11. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HALO: 18. 1% to $78. 33.

In this comparison, JNJ (2.

2% yield) pays a dividend. HALO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +136. 2% 10Y return). Both have compounded well over 10 years (JNJ: +136. 2%, HALO: +598. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HALO is a small-cap high-growth stock; JNJ is a large-cap quality compounder stock. JNJ pays a dividend while HALO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.